Excellence in Scientific Discovery

The Institute's comprehensive investigations extend from the earliest phase of basic discovery to the development of new cancer diagnostics, treatment protocols and prevention strategies

Research Programs

Basic, clinical and translational studies into the biology of cancer and the factors that contribute to its onset and growth.


Shared Resources

The most sophisticated technologies and research protocols are offered to SCI members through a number of core facilities.


Key Initiatives

Inter-disciplinary teams of collaborative investigators partner to foster discovery, application and translation of scientific knowledge.


Institute Membership

Scientists and physicians from a wide range of disciplines, all dedicated to reducing the burden of cancer.


News & Publications

Publications, press releases and news are shared with scientists, physicians, patients and friends of the Institute.


Funding Opportunities

Internal and external sources of support for both established cancer research programs and promising new ideas.  


Clinical Trial Support

The Cancer Clinical Trials Office provides regulatory and administrative services to SCI members conducting clinical trials.  


Training Opportunities

Education and professional development designed to train the next generation of cancer researchers and physicians.



National Cancer Institute Designation

News & Publications

  • Understanding ‘chemo brain’

    Three types of cells in the brain’s white matter show interwoven problems during the cognitive dysfunction that follows treatment with the cancer drug methotrexate, Stanford neuroscientists have found.


  • No survival benefit with new cancer drug

    Cisplatin chemotherapy can bring lasting adverse health effects, but a new, presumably less-toxic alternative is not as effective at promoting survival, according to a large, Stanford-led trial.


  • Study: Anti-CD47 cancer therapy safe

    An immunotherapy conceived at Stanford appeared safe in an early clinical trial. Half of the participants responded positively to the treatment, aimed at triggering macrophages to engulf cancer cells, the researchers reported.